APO Research
Talk to an analyst

APO RESEARCH · REPORT

Major Histocompatibility Complex

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Major Histocompatibility Complex Market Outlook and Growth Opportunities 2026

2 January 2026198 pages

Choose your research edition.

Industry ResearchMajor Histocompatibility Complex Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Major Histocompatibility Complex Industry Growth and Trends Forecast to 203286 pages · $3,450 USDMarket StructureGlobal Major Histocompatibility Complex Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Major Histocompatibility Complex Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal Major Histocompatibility Complex Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Major Histocompatibility Complex market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Major Histocompatibility Complex is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Major Histocompatibility Complex is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Major Histocompatibility Complex is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Major Histocompatibility Complex market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Major Histocompatibility Complex market include Santa Cruz Biotechnology, ProImmune, Novus Biologicals, Miltenyi Biotec, Creative BioMart and Abbexa, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Major Histocompatibility Complex market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Major Histocompatibility Complex and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Major Histocompatibility Complex revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Major Histocompatibility Complex market.

Major Histocompatibility Complex Segment by Company

Santa Cruz Biotechnology

ProImmune

Novus Biologicals

Miltenyi Biotec

Creative BioMart

Abbexa

Major Histocompatibility Complex Segment by Type

MHC Class II

MHC Class III

MHC Class I

Major Histocompatibility Complex Segment by Application

Medical Care

Research

Other

Major Histocompatibility Complex Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Major Histocompatibility Complex status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Major Histocompatibility Complex key companies, revenue, market share, and recent developments.

3. To split the Major Histocompatibility Complex breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Major Histocompatibility Complex market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Major Histocompatibility Complex significant trends, drivers, influence factors in global and regions.

6. To analyze Major Histocompatibility Complex competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Major Histocompatibility Complex market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Major Histocompatibility Complex and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Major Histocompatibility Complex.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Major Histocompatibility Complex industry.

Chapter 3: Detailed analysis of Major Histocompatibility Complex company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Major Histocompatibility Complex in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Major Histocompatibility Complex in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Major Histocompatibility Complex Industry Trends Table 2. Major Histocompatibility Complex Industry Drivers Table 3. Major Histocompatibility Complex Industry Opportunities and Challenges Table 4. Major Histocompatibility Complex Industry Restraints Table 5. Global Major Histocompatibility Complex Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Major Histocompatibility Complex Revenue Share by Company (2021-2026) Table 7. Global Major Histocompatibility Complex Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Major Histocompatibility Complex Key Company Manufacturing Base & Headquarters Table 9. Global Major Histocompatibility Complex Company, Product Type & Application Table 10. Global Major Histocompatibility Complex Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Major Histocompatibility Complex by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of MHC Class II Table 15. Significant Companies of MHC Class III Table 16. Significant Companies of MHC Class I Table 17. Global Major Histocompatibility Complex Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 18. Global Major Histocompatibility Complex Sales Value by Type (2021-2026) & (US$ Million) Table 19. Global Major Histocompatibility Complex Sales Value by Type (2027-2032) & (US$ Million) Table 20. Global Major Histocompatibility Complex Sales Value Share by Type (2021-2026) Table 21. Global Major Histocompatibility Complex Sales Value Share by Type (2027-2032) Table 22. Significant Companies of Medical Care Table 23. Significant Companies of Research Table 24. Significant Companies of Other Table 25. Global Major Histocompatibility Complex Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Major Histocompatibility Complex Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Major Histocompatibility Complex Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Major Histocompatibility Complex Sales Value Share by Application (2021-2026) Table 29. Global Major Histocompatibility Complex Sales Value Share by Application (2027-2032) Table 30. Global Major Histocompatibility Complex Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Major Histocompatibility Complex Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Major Histocompatibility Complex Sales Value Share by Region (2021-2026) Table 33. Global Major Histocompatibility Complex Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Major Histocompatibility Complex Sales Value Share by Region (2027-2032) Table 35. Global Major Histocompatibility Complex Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Major Histocompatibility Complex Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Major Histocompatibility Complex Sales Value Market Share by Country (2021-2026) Table 38. Global Major Histocompatibility Complex Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Major Histocompatibility Complex Sales Value Market Share by Country (2027-2032) Table 40. Santa Cruz Biotechnology Company Information Table 41. Santa Cruz Biotechnology Business Overview Table 42. Santa Cruz Biotechnology Major Histocompatibility Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Santa Cruz Biotechnology Major Histocompatibility Complex Product Portfolio Table 44. Santa Cruz Biotechnology Recent Development Table 45. ProImmune Company Information Table 46. ProImmune Business Overview Table 47. ProImmune Major Histocompatibility Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. ProImmune Major Histocompatibility Complex Product Portfolio Table 49. ProImmune Recent Development Table 50. Novus Biologicals Company Information Table 51. Novus Biologicals Business Overview Table 52. Novus Biologicals Major Histocompatibility Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Novus Biologicals Major Histocompatibility Complex Product Portfolio Table 54. Novus Biologicals Recent Development Table 55. Miltenyi Biotec Company Information Table 56. Miltenyi Biotec Business Overview Table 57. Miltenyi Biotec Major Histocompatibility Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Miltenyi Biotec Major Histocompatibility Complex Product Portfolio Table 59. Miltenyi Biotec Recent Development Table 60. Creative BioMart Company Information Table 61. Creative BioMart Business Overview Table 62. Creative BioMart Major Histocompatibility Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Creative BioMart Major Histocompatibility Complex Product Portfolio Table 64. Creative BioMart Recent Development Table 65. Abbexa Company Information Table 66. Abbexa Business Overview Table 67. Abbexa Major Histocompatibility Complex Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Abbexa Major Histocompatibility Complex Product Portfolio Table 69. Abbexa Recent Development Table 70. Research Programs/Design for This Report Table 71. Authors List of This Report Table 72. Secondary Sources Table 73. Primary Sources List of Figures Figure 1. Major Histocompatibility Complex Product Image Figure 2. Global Major Histocompatibility Complex Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Major Histocompatibility Complex Market Size (2021-2032) & (US$ Million) Figure 4. Global Major Histocompatibility Complex Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. MHC Class II Image Figure 8. MHC Class III Image Figure 9. MHC Class I Image Figure 10. Global Major Histocompatibility Complex Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 11. Global Major Histocompatibility Complex Sales Value Share 2021 VS 2025 VS 2032 Figure 12. Global Major Histocompatibility Complex Sales Value Share by Type (2021-2032) Figure 13. Medical Care Image Figure 14. Research Image Figure 15. Other Image Figure 16. Global Major Histocompatibility Complex Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Major Histocompatibility Complex Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Major Histocompatibility Complex Sales Value Share by Application (2021-2032) Figure 19. Global Major Histocompatibility Complex Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Major Histocompatibility Complex Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Major Histocompatibility Complex Sales Value (2021-2032) & (US$ Million) Figure 22. North America Major Histocompatibility Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Major Histocompatibility Complex Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Major Histocompatibility Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Major Histocompatibility Complex Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Major Histocompatibility Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Major Histocompatibility Complex Sales Value (2021-2032) & (US$ Million) Figure 28. South America Major Histocompatibility Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Major Histocompatibility Complex Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Major Histocompatibility Complex Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Major Histocompatibility Complex Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • MHC Class II
  • MHC Class III
  • MHC Class I
Applications
  • Medical Care
  • Research
  • Other
Companies covered
  • Santa Cruz Biotechnology
  • ProImmune
  • Novus Biologicals
  • Miltenyi Biotec
  • Creative BioMart
  • Abbexa

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Major Histocompatibility Complex Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Major Histocompatibility Complex Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Major Histocompatibility Complex Market Dynamics
  1. 2.1 Major Histocompatibility Complex Industry Trends
  2. 2.2 Major Histocompatibility Complex Industry Drivers
  3. 2.3 Major Histocompatibility Complex Industry Opportunities and Challenges
  4. 2.4 Major Histocompatibility Complex Industry Restraints
3 Major Histocompatibility Complex Market by Company
  1. 3.1 Global Major Histocompatibility Complex Company Revenue Ranking in 2025
  2. 3.2 Global Major Histocompatibility Complex Revenue by Company (2021-2026)
  3. 3.3 Global Major Histocompatibility Complex Company Ranking (2024-2026)
  4. 3.4 Global Major Histocompatibility Complex Company Manufacturing Base and Headquarters
  5. 3.5 Global Major Histocompatibility Complex Company Product Type and Application
  6. 3.6 Global Major Histocompatibility Complex Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Major Histocompatibility Complex Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Major Histocompatibility Complex Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Major Histocompatibility Complex Market by Type
  1. 4.1 Major Histocompatibility Complex Type Introduction
  2. 4.1.1 MHC Class II
  3. 4.1.2 MHC Class III
  4. 4.1.3 MHC Class I
  5. 4.2 Global Major Histocompatibility Complex Sales Value by Type
  6. 4.2.1 Global Major Histocompatibility Complex Sales Value by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Major Histocompatibility Complex Sales Value by Type (2021-2032)
  8. 4.2.3 Global Major Histocompatibility Complex Sales Value Share by Type (2021-2032)
5 Major Histocompatibility Complex Market by Application
  1. 5.1 Major Histocompatibility Complex Application Introduction
  2. 5.1.1 Medical Care
  3. 5.1.2 Research
  4. 5.1.3 Other
  5. 5.2 Global Major Histocompatibility Complex Sales Value by Application
  6. 5.2.1 Global Major Histocompatibility Complex Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Major Histocompatibility Complex Sales Value by Application (2021-2032)
  8. 5.2.3 Global Major Histocompatibility Complex Sales Value Share by Application (2021-2032)
6 Major Histocompatibility Complex Regional Value Analysis
  1. 6.1 Global Major Histocompatibility Complex Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Major Histocompatibility Complex Sales Value by Region (2021-2032)
  3. 6.2.1 Global Major Histocompatibility Complex Sales Value by Region: 2021-2026
  4. 6.2.2 Global Major Histocompatibility Complex Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Major Histocompatibility Complex Sales Value (2021-2032)
  7. 6.3.2 North America Major Histocompatibility Complex Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Major Histocompatibility Complex Sales Value (2021-2032)
  10. 6.4.2 Europe Major Histocompatibility Complex Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Major Histocompatibility Complex Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Major Histocompatibility Complex Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Major Histocompatibility Complex Sales Value (2021-2032)
  16. 6.6.2 South America Major Histocompatibility Complex Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Major Histocompatibility Complex Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Major Histocompatibility Complex Sales Value Share by Country, 2025 VS 2032
7 Major Histocompatibility Complex Country-level Value Analysis
  1. 7.1 Global Major Histocompatibility Complex Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Major Histocompatibility Complex Sales Value by Country (2021-2032)
  3. 7.2.1 Global Major Histocompatibility Complex Sales Value by Country (2021-2026)
  4. 7.2.2 Global Major Histocompatibility Complex Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Major Histocompatibility Complex Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Major Histocompatibility Complex Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Major Histocompatibility Complex Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Santa Cruz Biotechnology
  2. 8.1.1 Santa Cruz Biotechnology Company Information
  3. 8.1.2 Santa Cruz Biotechnology Business Overview
  4. 8.1.3 Santa Cruz Biotechnology Major Histocompatibility Complex Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Santa Cruz Biotechnology Major Histocompatibility Complex Product Portfolio
  6. 8.1.5 Santa Cruz Biotechnology Recent Developments
  7. 8.2 ProImmune
  8. 8.2.1 ProImmune Company Information
  9. 8.2.2 ProImmune Business Overview
  10. 8.2.3 ProImmune Major Histocompatibility Complex Revenue and Gross Margin (2021-2026)
  11. 8.2.4 ProImmune Major Histocompatibility Complex Product Portfolio
  12. 8.2.5 ProImmune Recent Developments
  13. 8.3 Novus Biologicals
  14. 8.3.1 Novus Biologicals Company Information
  15. 8.3.2 Novus Biologicals Business Overview
  16. 8.3.3 Novus Biologicals Major Histocompatibility Complex Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Novus Biologicals Major Histocompatibility Complex Product Portfolio
  18. 8.3.5 Novus Biologicals Recent Developments
  19. 8.4 Miltenyi Biotec
  20. 8.4.1 Miltenyi Biotec Company Information
  21. 8.4.2 Miltenyi Biotec Business Overview
  22. 8.4.3 Miltenyi Biotec Major Histocompatibility Complex Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Miltenyi Biotec Major Histocompatibility Complex Product Portfolio
  24. 8.4.5 Miltenyi Biotec Recent Developments
  25. 8.5 Creative BioMart
  26. 8.5.1 Creative BioMart Company Information
  27. 8.5.2 Creative BioMart Business Overview
  28. 8.5.3 Creative BioMart Major Histocompatibility Complex Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Creative BioMart Major Histocompatibility Complex Product Portfolio
  30. 8.5.5 Creative BioMart Recent Developments
  31. 8.6 Abbexa
  32. 8.6.1 Abbexa Company Information
  33. 8.6.2 Abbexa Business Overview
  34. 8.6.3 Abbexa Major Histocompatibility Complex Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Abbexa Major Histocompatibility Complex Product Portfolio
  36. 8.6.5 Abbexa Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst